Laboratory for Advanced Medicine & Health

LAMH is an Al-driven cancer screening and diagnostic innovation enter- prise, founded by international business leaders, top scientists and medical professionals, with the idea of "making cancer screening earlier, more accurate,more accessible and easierLAMH is the "Global first and only" early cancer screening and di- agnostic company that is fully established in China and the United States, the world's two largest economies, for technology de- velopment,manufacturing,NMPA/FDA approval and commercialization.On June 20.2023.Guangzhou Elitehealth Biotech Co.LTD.a GMP entity of LAMH, accomplished a remarkable milestone by obtaining the world's first (and currently the only)registration certificate for liver cancer early screening from the China National Medical Products Administration(NMPA).The Company successfully launched its liver cancer early screening products,甘倍康and HelioLiver in China and the U.S. respectivelyproviding accurate, accessible,and user-friendly screening and diagnostic solutions for liver cancer. This groundbreaking achievement has revolutionized the landscape of clinical screening, diagnosis, and monitoring of liver cancer, thereby establishing and enhancing the standards and protocols for cancer screening in both coun- tries. By adopting a value-based medicine approach, the company aims to address the challenges associated with early cancer screening,diagnosis, and treatment. effectively meeting the unmet clinical and health needs in both China and the United States.

The Chinese independent entity LAMH is headquartered in the Pazhou Central Business District, Guangzhou. It has a research and registration center in the Beijing Economic and Technological Development Zone, Southern and Northern medical testing labs (ICL) compliant with PCR and NGS standards in Guangzhou's Biotech Island and Beijing's Yizhuang respectively. A NMPA-assessed IVD GMP factory is located in Guangzhou's Science City. The American independent entity Helio Genomics is based in Irvine, California, with a certified CLIA and CAP central lab in Indiana.


Making cancer screening earlier,

more accurate, accessible and convenient.


A technology-driven global leader

in early cancer detection.


Result-oriented, customer-centric,

and people-oriented.

Core Technology
A technology-driven global leader in early cancer detection.
The world's first large scale liver cancer early screening research results based on cfDNA methylation technology, pioneering the use of cfDNA methylation for early cancer screening.
LAMH research results show that methylation markers can be used effectively in the diagnosis and prognosis of breast, colorectal, liver and lung cancers.
CHALM-cell heterogeneity-adjusted methylation quantitative analysis method.
Research published in the Journal of the American Association for the Study of Liver Cancer has shown that the LAMH HelioLiver Test, a liver cancer early screening product, can accurately detect early stage liver cancer.
IvyGene® Liver
Hepatocellular carcinoma gene
methylation test
IvyGene®Liver Plus
Hepatocellular carcinoma gene
methylation test
lvyGene® PLUS
Early and accurate cancer screening
Core Team
Zeyue Zhang
Zeyue Zhang

Mr. Zeyue Zhang is the CEO of LAMH, leading the company to obtain the world's first National Pharmacovigilance Certificate in the field of early liver cancer screening, and becoming the only company to obtain full reimbursement code and pricing from US commercial insurance. Dedicated to the cause of cancer prevention and treatment, he has worked in well-known domestic gene companies such as BGI and CapitalBio MedLab, as well as global pharmaceutical companies such as Eli Lilly, Roche, and Novartis, and also has experience in management of start-up companies, multinational enterprises, well-known private enterprises and state-owned enterprises. He is a recipient of the《Fortune》‘40 under 40 Business Leader’.

Shu Li
Shu Li

Dr. Shu Li is a successful entrepreneur in the biomedical field. He served as senior vice president of Conexant Systems, vice president and general manager of Honeywell Commercial Spare Parts, and held senior management positions in Motorola and Intel. Dr. Li Shu is a member of the Advisory Board of the University of California, Irvine (Business School), and has also served as a faculty member at the University of Arizona. He holds 6 US and international patents.

Bachelor of Automatic Control from Huazhong University of Science and Technology;
Degree in Electrical Engineering from the University of Illinois at Urbana-Champaign;
PhD in Applied Science from Harvard University.

Company History
The world's earliest methylation technology company
Obtains UCSD's global first methylation cancer screening technology.
LAMH was officially established.
Granted PCT patent
Including methylation markers for solid tumors, colorectal cancer, lung cancer, leukemia, breast cancer, ovarian cancer, and liver cancer.
Granted Chinese patents
For methylation markers for diagnosing liver cancer and lung cancer, as well as methylation markers for cancer diagnosis.
Completed NMPA registration for liver cancer detection
Becoming the first company to pass China's liver cancer methylation detection IVD registration.
The first to launch China's NMPA liver cancer clinical trial
Receive a major project from the Ministry of Science and Technology of China
And jointly develop Chinese population-based liver cancer, colorectal cancer, and lung cancer screening standards and technical routes.
Completed NMPA liver cancer clinical trial and releases clinical trial data.
Completed product standardization for colorectal cancer early screening
multi-omics blood products by PCR laboratory acceptance.
Commercialization of liver cancer products officially launches.
LAMH launches commercialization of scale liver cancer LDT testing products
Pan-cancer early screening multi-omics blood products marker screening
and five-cancer early screening LDT products launched
Launches MR liver cancer recurrence monitoring project.
LAMH was recognized as the first batch of "National High-tech Enterprises" in 2022.
莱盟健康LAMH MR肝癌复发监测项目启动
Latest News
Cutting-edge cooperation
Stanford Medicine
Johns Hopkins
Harvard Medical School
Cleveland Clinic
UCI Rvine
Uc San Diego
Purdue University
University Of Arizona
U Health
Moffitt Cancer Center
Ochsner Health
Cedars Sinai
Listed in no particular order
《Nature Materials》
Researchers analyzed ctDNA methylation models of 1098 liver cancer patients and 835 normal individuals, and established integrated diagnostic models (AUC: 0.969) and comprehensive prognostic models with 10 and 8 methylation sites, respectively, which possess high sensitivity and specificity. These models were used for real-time tumor load detection, treatment response, recurrence monitoring and prognosis evaluation of liver cancer patients. Compared with AFP detection, the integrated diagnostic model has higher sensitivity and specificity in stages I, II, and III tumors, while AFP does not change much except in stages III and IV liver cancer.
Read more
Researchers used AI training on methylation data from TCGA and Chinese clinical samples in NGS technology, and screened out specific methylation models for four common cancers (breast cancer, colorectal cancer, liver cancer, and lung cancer). The verification results showed that the methylation model can detect the four types of cancer with an accuracy rate of over 95% in the Chinese population.
Read more
《Nature Communications》
The current methylation quantitative analysis method does not consider the heterogeneity of cells during sequencing, which may lead to weak correlation between methylation analysis results and gene expression data. The CHALM algorithm helps us better reveal the function of DNA methylation and its correlation with gene expression.
Read more
《Nature Materials》
HelioLiver Test is a blood test that combines cfDNA methylation patterns with tumor protein markers analysis. In a double-blind, multi-center clinical validation study of 122 liver cancer patients and 125 cirrhosis patients, HelioLiver Test had a sensitivity of 85% for detecting liver cancer, and 76% for early-stage (AJCC I and II) liver cancer, while the specificity was also up to 91%, which is significantly better than AFP and GALAD models.
Read more